Ductal infiltrating carcinoma (DIC) of the breast is the most common and potentially aggressive form of cancer. Knowledge of proteomic profiles, attained both in vivo and in vitro, is fundamental to acquire as much information as possible on the proteins expressed in these pathologic conditions. We used the breast cancer cell line 8701-BC, established from a primary DIC, with the aim of contributing to the databases on mammary cancer cells, which in turn will be very useful for the identification of differentially expressed proteins in normal and neoplastic cells. Within an analysis window comprising about 1750 discernible spots, we have at present catalogued 84 protein spots. The proteins for which an identity was assigned were identified essentially using gel comparison, N-terminal (Nt) microseqencing and immune detection. Among the protein spots Nt-microsequenced, sixteen corresponded to known proteins, four resulted as modified, relative to matching sequences deposited on databases, and seven were unknown. These modified or novel sequences are thus of potential interest to the knowledge of breast cancer proteomics and its applications.
Introduction
Breast cancer is the most common cancer among Western women. However, breast cancer is not a single disease, but includes several different forms that can be grouped into invasive and noninvasive histotypes. Among the invasive, ductal infiltrating carcinoma (DIC) is the most common and aggressive form [1] . This kind of carcinoma usually has a poor prognosis, and represents the standard histotype with which the other less frequent subtypes are compared. Carcinomas are potentially malignant tumors of epithelial origin, which, once genetically initiated, grow, progress, invade and spread from one organ or tissue to another with a common phenotype, regardless of their individual derivation. The major cellular changes involved in the conversion of normal to malignant breast are the progressive loss of the stationary epithelial phenotype and the acquisition of a mesenchimallike phenotype, correlated with the ability to migrate and invade surrounding and distant tissues, even under conditions of low oxygen supply. These features are related to defects in a multiplicity of genes and proteins, whose number, identity and functions are still far from understood. The proteomic approach is therefore considered at present to be the most promising to investigate protein expression and function and to monitor cancer related defects of large numbers of proteins within a cell or tissue. However, some limitations to this approach are intrinsic to the experimental system: on the one hand primary tumor biopsies may contain several different cell types other than carcinoma cells, and laser-capture microdissected sections [2] may include a large amount of proteins resident in the extracellular interstitium. On the other hand neoplastic cells in culture, being free of any tissue components, may not represent their exact in vivo counterparts. In spite of this limitation, cancer cells in culture represent a powerful substitute for the study of molecular and cell biology. Therefore, several laboratories, including our own, have developed appropriate in vitro models of normal and neoplastic cells for biological and molecular assays including the recent approach of cDNA microarrays [3] and proteomics [4] [5] [6] [7] .
Among the breast cancer cell lines described so far in the literature, 8701-BC [8] [9] [10] deserves particular attention, since it was established from a primary DIC, that is, before the clonal selection of the metastatic process. This cell line maintains a number of properties in culture that are characteristic of mammary tumor cells e.g. expression of cytokeratin 8 and 18 (typical of the mammary lumenal phenotype), loss of polarised morphology, accelerated growth rate, release of matrix metalloproteases, loss of contact inhibition and formation of multilayered colonies (domes), low dependence on serum and growth factor and the ability to invade matrigel and nude mice. These properties are clearly distinguished from normal mammary cells in culture (i.e. the HB2 derived from lumenal epithelial cells [11] ), which maintain the polarised phenotype, establish correct cell-cell interactions, do not invade in vitro and in vivo and are dependent on serum. We have thus used this cell line model for the analysis of protein expression profiles, with the aim of contributing to the databases on mammary cancer cells present in the literature and on the internet, which in turn will be very useful for the identification of differentially expressed proteins in normal and neoplastic cells. Within an analysis window comprising about 1750 discernible spots, we have at present recorded 84 protein spots, utilising following methods: N-terminal (Nt) microsequencing (31), immune detection (23) and gel matching (30) with available maps at the 2-DE databases (http://www.expasy.ch/ ch2d/2d-index.html). Among the protein spots Nt-microsequenced, sixteen corresponded to known proteins, four were modified relative to matching sequences deposited on databases, seven were unknown and four were N-blocked.
Materials and methods

Cell culture
For the experiments described, we used the neoplastic cell line 8701-BC under the conditions previously described [8] . Briefly, the cells were seeded at a concentration of 1-2 6 10 5 /cm 2 in RPMI 1640 culture medium (Gibco, Paisley, UK), supplemented with 10% foetal calf serum (Gibco) and antibiotics (100 units/mL penicillin and 100 mg/mL streptomycin), and grown in a humidified incubator with 3% CO 2 in air at 377C. As nontumoral control we used the HB2 human mammary epithelial cell line, kindly given by Dr. J. Taylor-Papadimitriou (Imperial Cancer Research Fund, London, UK) and currently cultivated in our lab under the conditions described by Bartek and coworkers [11] .
Sample preparations
Cells were grown to confluence and then incubated with three changes of serum-free medium over 24-48 h. After washing with ice-cold PBS, they were carefully scraped and incubated on ice for 30 min with RIPA buffer (50 mM Tris pH 7.5, 0.1% Nonidet P-40, 0.1% deoxycholate, 150 mM NaCl, 4 mM EDTA and a mixture of protease inhibitors, 0.01% aprotinin, 10 mM sodium pyrophosphate, 2 mM sodium orthovanadate, 1 mM PMSF). The total cellular lysate was centrifuged at 14 000 rpm for 8 min to clear cell debris, and the supernatant dialysed against ultrapure distilled water, lyophilised and stored at -807C until analysis. Culture media were collected from confluent cells deprived of serum, extensively dialysed against ultrapure distilled water; lyophilised and stored at -807C until used. Protein concentration in the cellular extracts and culture media was determined using the Bradford method [12] .
Two-dimensional gel electrophoresis
Aliquots of the dried cell lysate were solubilised in a buffer containing 4% CHAPS, 40 mM Tris, 65 mM DTE (1,4-dithioerythritol) and a trace amount of bromophenol blue in 8 M urea. The first dimensional separation was performed at 207C on commercial sigmoidal immobilised pH gradient strips (IPGs), 18 cm long with pH range 3.5-10, (Amersham Pharmacia Biotech, Uppsala, Sweden), essentially as described by Görg et al. [13] and Bjellqvist et al. [14] . Strips were rehydrated in 8 M urea, 2% CHAPS, 10 mM DTE and 0.5% carrier ampholytes (Resolyte 3.5-10; BDH, Merck, Milan, Italy). Aliquots of 45 mg (analytical gels) or 1.5 mg (preparative gels) of total proteins were applied to the gel strip. IEF was carried out by linearly increasing the voltage from 200 to 3500 V during the first 3 h, after which focusing was continued at 8000 V for 8 h. After the run the IPG strips were equilibrated with a solution containing 6 M urea, 30% glycerol, 2% SDS, 0.05 M Tris-HCl pH 6.8 and 2% DTE for 12 min, in order to resolubilise proteins and reduce disulfur bonds. The -SH groups were then blocked by substituting the DTE with 2.5% iodoacetamide in the equilibration buffer. The focused proteins were then separated on 9-16% linear gradient polyacrylamide gels (SDS-PAGE) with a constant current of 40 mA/gel at 107C. Gels were stained with ammoniacal silver nitrate as described by Hochstrasser et al. [15] .
Image acquisition and data analysis
Silver stained gels were digitised using a computing densitometer and processed with the Melanie 3 computer system (GeneBio, Geneva, Switzerland). As internal standard for gel calibration we used an array of 15 features of the cell lysate, whose pI and M r were formerly estimated by interpolation with serum proteins that had comigrated with the whole cell lysate. Background subtraction was performed by considering only the common spots of three different gels of the same sample matched together. For figure presentations, images were transferred to Adobe Photoshop and PowerPoint programs.
Protein identification
The proteins for which an identity was assigned were identified essentially using gel comparison [16] , Nt microseqencing and immune detection (see Sections 2.6 and 2.7). For protein identification by computer gel matching we used the liver map (http://www.expasy.ch/cgi-bin/ map2/def?LIVER_HUMAN), the colorectal adenocarcinoma DL-1 cell line map (http://www.expasy.ch/cgi-bin/ map2/def?DLD1_HUMAN), the gastrocnemius muscle map (http://www.expasy.ch/cgi-bin/map2/def?MUSCLE _MOUSE) deposited in the SWISS-2DPAGE, and the human breast ductal carcinoma map (http://www.biomol.unisi.it/cgi-bin/map2/def?BREAST_DC_HUMAN) deposited in the SIENA-2DPAGE database.
Protein microsequencing
N-terminal microsequencing was performed by automated Edman degradation in a protein sequenator (Procise 491, Applied Biosystems, Monza, Italy) on protein samples electrotransferred onto PVDF membranes (Millipore, Immobilon-PTM; Sigma, Milan, Italy) at 50 V for 30 min at 47C. The SWISS-PROT (ScanProsite) and EMBL (Bic 2) databases were used for on-line sequence similarity search at http://www.expasy.ch/tools/#similarity.
Western blotting
For immune detection the 2-D IPG gels were electrotransferred onto nitrocellulose membrane (HyBond ECL, Amersham) at 50 V for 1 h at 47C. After electrotransfer, the membranes were stained with Ponceau S (Sigma) and the separation pattern recorded in order to perform subsequent gel matching. The membranes were then probed with one of the following monoclonal antibodies: anti-cytokeratin-8 and 18 (Chemicon International, Milan, Italy), antivimentin (Novocastra, DBA Italia, Milan, Italy), and anti-alpha-enolase (courtesy of Prof. S. Feo and colleagues, [17] ). The reaction was revealed by the ECL detection system, using high performance films (Hyperfilm ECL, Amersham).
Results
In Fig. 1A to C phase contrast micrographs of the 8701-BC cell culture are shown at 48 h, 1 week and 10 d from seeding, compared with HB2 cells derived from normal mammary epithelium at the same growth time (Fig. 1D-F) . As can be observed from these micrographs, the neoplastic cells display an apolarised morphology with irregular profiles; they spread over the substrate with emission of spikes and once confluence is reached they overlap, forming distinctive domes (Fig. 1C) . This growth modality is typical of neoplastic cells and is dramatically evident when compared with nontumoral cells, which maintain in vitro the polygonal morphology of epithelial cells, establish extensive cell-cell contact forming orderly islands and stop growing once confluent, being responsive to contact inhibition signals.
Since cell morphology is the first manifestation of cell phenotype and the phenotype of a given cell type is, in turn, determined by the activation status of its genome and by the composition of its protein complement in a given moment of cell life, the proteomic pattern represents the molecular support for phenotyping cells and for describing disease associated alterations, which may involve an unpredictable number of known and unknown proteins, with structural and functional roles in the cell. With this aim, we compared the proteomic profiles of sets of proteins from 8701-BC cells vs. HB2 nontumoral mammary cells reported elsewhere [18] . In the present report we extend previous data with validation and additional identification of new sets of proteins. Figure 2 shows the proteomic map of the 8701-BC cell lysate in which, among the 1750 spots detected by the Melanie system after background subtraction, we have identified and catalogued 84 protein spots. The proteins to which identities were assigned are marked with labels corresponding to the accession number of the SWISS-PROT database, which also includes the major isoelectric variants of assigned proteins. The unknown proteins are labelled with the abbreviations UBC (unknown breast cancer) or UBCS (unknown breast cancer secreted), followed by the approximate molecular mass (kDa). The last category includes three proteins found in the 2-D IPG map of the conditioned medium of the 8701-BC cells, which was matched with the cell lysate map. Figure 3 shows the 2-D gel section of the conditioned medium, which includes the Nt-microsequenced spots, corresponding to the secreted proteins with unknown identity. Table I summarises the catalogue of the protein spots described in Fig. 2 with the following indications: AC and Entry name, corresponding respectively to the accession numbers and the abbreviations used in the SWISS-PROT database, protein name, experimental pI and experimental M r , method of protein identification (GM: gel matching (30), Nt-Mi: N-terminal microsequencing (31), WB: Western blot (23) ) and N-terminal sequences, along with substitutions (when present) relative to similar sequences deposited in the protein databases. Within the proteins N-terminal sequenced, sixteen corresponded to proteins already present in the databases, four appeared to be modified relative to the matching proteins, seven resulted unknown and four were N-blocked.
Among the proteins present in the databases, two have not been described previously in breast cancer, i.e. the ubiquitin thiolesterase L1 and the glycoprotein GC1QBP (MA32). The four proteins showing alterations concerned thioredoxin, in which the threonine in position 8 is substituted with alanine; a truncated and slightly more basic form of annexin I (pI/M r 8.04/25752, starting from residue 26) displaying two substitutions, namely serine 27 and glycine 30, both replaced by isoleucine; a truncated form of alpha-enolase (starting from residue 57) and a shortened form of glyceraldehyde 3-phosphate dehydrogenase starting with regular N-terminal residues. In addition, seven protein sequences, some of which showed ambiguities, did not match any known sequence deposited in the databases. The protein spots released into the medium by the 8701-BC cells included two unknown sequences (UBCS) and a small peptide (pI/M r 5.97/ 17100) matching residues 4199-4207 of the perlecan core protein (PGMB).
Finally, the protein identified by immune detection regarded an isoelectric series corresponding to alphaenolase, coincident with the silver stain pattern, and a group of intermediate filament proteins. These included seven spots that bound to anticytokeratin-8, five to anticytokeratin-18 and eight to antivimentin (Fig. 4A-C) . In parallel, the immune detection for intermediate filaments was also performed on the HB2 cell lysate. In this case the reaction was negative for the antivimentin assay, and positive for both anticytokeratins (Fig. 4D-F) . However, as shown in Fig. 4 , the number and the isoelectric variants of both cytokeratins were dissimilar from those observed in the 8701-BC cell map. As the majority of the cytoskeletal proteins were almost indiscernible in the silver stained gels, their attribution to the proteomic map presented in Fig. 2 was achieved by gel matching with the corresponding pattern on the ECL film.
Discussion
Cancer is a somatic gene disease, but at present it is not known how many genes are directly or indirectly involved in the transition from normal to malignant cells. Abnormalities are expected at several levels: gene alterations, qualitative/quantitative protein expression, primary and post-translational modifications of protein structure or cytoplasmic delocalization, any of which may ultimately affect cell function and behavior. Therefore the first goal is to obtain the proteomic profiles of normal and neoplastic cells and tissues and to identify differentially expressed proteins as putative contributors to specific malignancies. Hence the proteomic approach, by allowing the study of variations in gene expression under a large-scale of magnitude, now represents a powerful tool to ascertain which protein combination may play a key role in transformation and tumor progression and apply the obtained information to new clinical strategies.
In the present work we aim to provide a contribution to the knowledge of proteomic profiles of breast cancer using the well-characterised 8701-BC cell line. As stated in Section 1, this cell line is derived from a primary DIC and maintains the phenotypic features of tumorigenic cells in culture, i.e. the ability to overlap and form distinctive domes, the loss of polarity and acquisition of motile behavior and an invasive capacity both in vitro and in vivo. Here we demonstrate for the first time that these cells coexpress several forms of cytokeratins (-8 and -18) and vimentin, which are respectively cytoskeletal markers of lumenal mammary epithelium [19] and of mesenchimal cells. These proteins were identified by immune detection on 2-D IPG gels as multiple forms, many of which are not included in current databases. The co-expression of cytokeratins and vimentin by the 8701-BC cells is a further demonstration that many features related to cancer cells (i.e. loss of polarity, defective cell-cell contacts, increased motility) reflect an epithelial-mesenchymal transition, as postulated for many carcinomas of different origin [20] . This epithelial-mesenchymal transition is not due to the in vitro culture, since HB2 cells used as control were negative for the antivimentin reaction. The proteomic profile of 8701-BC cells, at present a collection of 84 protein spots, including known proteins, and their isoforms and unknown or modified proteins, were identified by means of N-terminal microsequencing, immune detection and gel matching with reference gels.
Two of the proteins with known identities have not been identified before in breast cancer proteomics: the first is the glycoprotein GC1QBP (MA32), known to bind the globular heads of C1Q, thus inhibiting C1 activation, but with unknown function in vivo; the second is UBL1 (ubiquitin thiolesterase L1), a thiol protease that removes ubiquitin from ubiquitinated proteins and prevents them from targeted degradation by proteasomes, first described as a neurospecific marker [21, 22] . A third protein spot, identified by microsequencing as GST, an enzyme that conjugates reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles, was not found to be coincident with the corresponding protein spot described in breast cancer tissue [23] . Indeed the latter migrated with a pI/M r value of 5.40/23325, while on our map the value was 6.01/20635. This may indicate that the form identified on our map represents a variant of that previously described in breast cancer tissue, since genetic polymorphisms for GSTP1 in breast cancer have recently been demonstrated [24] . On the other hand, some authors have reported that the glutathione related detoxification system increases in human breast cancer in correlation with clinical and histopathological features [25] , and therefore GSTP1 is considered as a potential marker for breast tumors.
Among the proteins with substitutions we found a sequence similar to thioredoxin, where the threonine in position 8 is substituted with alanine. Human thioredoxin is a small redox protein that is overexpressed in a number of human primary tumors, where it is associated with rapid cell proliferation and inhibits apoptosis. Recently the possible association of thioredoxin with p53-dependent function, including DNA repair in breast cancer, has been suggested [26] .
In addition, two forms of annexin were also identified: one tagging with the full-length annexin I and the second starting from Res. 26 (pI/M r 8.04 25752) and bearing two substitutions: Ser 27-.Ile and Gly 30-.Ile. As is known, annexin is a calcium/phospholipid-binding protein which promotes membrane fusion and is involved in exocytosis [27] . It is also known that the ability of annexin I to promote membrane aggregation is highly dependent on the structure of the N-terminal domain [28] which includes the major phosphorylation sites (namely Tyr-20, a site for phosphorylation by the epidermal growth factor receptor kinase and Thr-23/Ser-27, the sites for phosphorylation by protein kinase C in vitro). Therefore it can be deduced that this truncated form of annexin has a different function, which remains to be elucidated.
Finally, a truncated form of alpha-enolase (starting from residue 57, pI/M r of 6.87/41563) and a shortened form of glyceraldehyde 3-phosphate dehydrogenase (pI/M r 8.46/34490) starting with regular N-terminal residues have been identified. These forms have not been described before and, due to the multifunctional role of both enzymes [29, 30] , the appearance of their derivative peptides in cancer cells is an additional finding of interest.
The protein spots released by the 8701-BC cells into the medium included two unknown sequences (UBCS) and a sequence matching residues 4199-4207 of the perlecan core protein (PGMB). A proportion of the expressed proteins in the proteomic map of 8701-BC appear to be the products of novel genes that are absent in the database, and therefore their inclusion in the database is a further contribution to the knowledge of breast cancer proteomics.
